Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Structure of a human intramembrane ceramidase explains enzymatic dysfunction found in leukodystrophy.

Vasiliauskaité-Brooks I, Healey RD, Rochaix P, Saint-Paul J, Sounier R, Grison C, Waltrich-Augusto T, Fortier M, Hoh F, Saied EM, Arenz C, Basu S, Leyrat C, Granier S.

Nat Commun. 2018 Dec 21;9(1):5437. doi: 10.1038/s41467-018-07864-w.

2.

Evaluation of eight melanocytic and neural crest-associated markers in a well-characterised series of 124 malignant peripheral nerve sheath tumours (MPNST): useful to distinguish MPNST from melanoma?

Gaspard M, Lamant L, Tournier E, Valentin T, Rochaix P, Terrier P, Ranchere-Vince D, Coindre JM, Filleron T, Le Guellec S.

Histopathology. 2018 Dec;73(6):969-982. doi: 10.1111/his.13740. Epub 2018 Oct 23.

PMID:
30137667
3.

[Carcinoma of unknown primary. Case no. 1].

Rochaix P.

Ann Pathol. 2018 Jun;38(3):168-169. doi: 10.1016/j.annpat.2018.04.010. Epub 2018 Jun 19. Review. French. No abstract available.

PMID:
29929747
4.

[Carcinoma of unknown primary. Case no. 2].

Rochaix P.

Ann Pathol. 2018 Jun;38(3):170-173. doi: 10.1016/j.annpat.2018.04.011. Epub 2018 Jun 19. Review. French. No abstract available.

PMID:
29929742
5.

[Carcinoma of unknown primary. Role of the pathologist in 2018: Introduction].

Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M.

Ann Pathol. 2018 Jun;38(3):164-197. doi: 10.1016/j.annpat.2018.04.008. Epub 2018 Jun 19. French. No abstract available.

PMID:
29929740
6.

Validation of the Complexity INdex in SARComas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas.

Le Guellec S, Lesluyes T, Sarot E, Valle C, Filleron T, Rochaix P, Valentin T, Pérot G, Coindre JM, Chibon F.

Ann Oncol. 2018 Aug 1;29(8):1828-1835. doi: 10.1093/annonc/mdy194.

PMID:
29860427
7.

Immunohistochemistry for Diagnosis of Metastatic Carcinomas of Unknown Primary Site.

Selves J, Long-Mira E, Mathieu MC, Rochaix P, Ilié M.

Cancers (Basel). 2018 Apr 5;10(4). pii: E108. doi: 10.3390/cancers10040108. Review.

8.

TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.

Bertrand F, Montfort A, Marcheteau E, Imbert C, Gilhodes J, Filleron T, Rochaix P, Andrieu-Abadie N, Levade T, Meyer N, Colacios C, Ségui B.

Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.

9.

RREB1-MKL2 fusion in biphenotypic "oropharyngeal" sarcoma: New entity or part of the spectrum of biphenotypic sinonasal sarcomas?

Siegfried A, Romary C, Escudié F, Nicaise Y, Grand D, Rochaix P, Barres B, Vergez S, Chevreau C, Coindre JM, Uro-Coste E, Le Guellec S.

Genes Chromosomes Cancer. 2018 Apr;57(4):203-210. doi: 10.1002/gcc.22521. Epub 2018 Jan 25.

PMID:
29266774
10.

Identification of a tumor-promoter cholesterol metabolite in human breast cancers acting through the glucocorticoid receptor.

Voisin M, de Medina P, Mallinger A, Dalenc F, Huc-Claustre E, Leignadier J, Serhan N, Soules R, Ségala G, Mougel A, Noguer E, Mhamdi L, Bacquié E, Iuliano L, Zerbinati C, Lacroix-Triki M, Chaltiel L, Filleron T, Cavaillès V, Al Saati T, Rochaix P, Duprez-Paumier R, Franchet C, Ligat L, Lopez F, Record M, Poirot M, Silvente-Poirot S.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):E9346-E9355. doi: 10.1073/pnas.1707965114. Epub 2017 Oct 12.

11.

Structural insights into adiponectin receptors suggest ceramidase activity.

Vasiliauskaité-Brooks I, Sounier R, Rochaix P, Bellot G, Fortier M, Hoh F, De Colibus L, Bechara C, Saied EM, Arenz C, Leyrat C, Granier S.

Nature. 2017 Apr 6;544(7648):120-123. doi: 10.1038/nature21714. Epub 2017 Mar 22.

12.

The AF-1-deficient estrogen receptor ERα46 isoform is frequently expressed in human breast tumors.

Chantalat E, Boudou F, Laurell H, Palierne G, Houtman R, Melchers D, Rochaix P, Filleron T, Stella A, Burlet-Schiltz O, Brouchet A, Flouriot G, Métivier R, Arnal JF, Fontaine C, Lenfant F.

Breast Cancer Res. 2016 Dec 7;18(1):123.

13.

Tumour lysis syndrome: an unexpected adverse event associated with ipilimumab.

Masson Regnault M, Ofaiche J, Boulinguez S, Tournier E, Rochaix P, Paul C, Lamant L, Meyer N.

J Eur Acad Dermatol Venereol. 2017 Feb;31(2):e73-e74. doi: 10.1111/jdv.13733. Epub 2016 Jun 3. No abstract available.

PMID:
27256718
14.

Highly Concordant Results Between Immunohistochemistry and Molecular Testing of Mutated V600E BRAF in Primary and Metastatic Melanoma.

Manfredi L, Meyer N, Tournier E, Grand D, Uro-Coste E, Rochaix P, Brousset P, Lamant L.

Acta Derm Venereol. 2016 Jun 15;96(5):630-4. doi: 10.2340/00015555-2326.

15.

Melanoma-expressed CD70 is involved in invasion and metastasis.

Pich C, Sarrabayrouse G, Teiti I, Mariamé B, Rochaix P, Lamant L, Favre G, Maisongrosse V, Tilkin-Mariamé AF.

Br J Cancer. 2016 Jan 12;114(1):63-70. doi: 10.1038/bjc.2015.412. Epub 2015 Dec 15.

16.

Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.

Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, Traverse-Glehen A, Rousset T, Quintin-Roue I, Petrella T, Emile JF, Amara N, Rochaix P, Chenard-Neu MP, Tasei AM, Menet E, Chomarat H, Costes V, Andrac-Meyer L, Michiels JF, Chassagne-Clement C, de Leval L, Brousset P, Delsol G, Lamant L.

Ann Oncol. 2016 Feb;27(2):306-14. doi: 10.1093/annonc/mdv575. Epub 2015 Nov 23.

17.

In vivo Effects in Melanoma of ROCK Inhibition-Induced FasL Overexpression.

Teiti I, Florie B, Pich C, Gence R, Lajoie-Mazenc I, Rochaix P, Favre G, Tilkin-Mariamé AF.

Front Oncol. 2015 Jul 14;5:156. doi: 10.3389/fonc.2015.00156. eCollection 2015.

18.

Blocking Tumor Necrosis Factor α Enhances CD8 T-cell-Dependent Immunity in Experimental Melanoma.

Bertrand F, Rochotte J, Colacios C, Montfort A, Tilkin-Mariamé AF, Touriol C, Rochaix P, Lajoie-Mazenc I, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.

Cancer Res. 2015 Jul 1;75(13):2619-28. doi: 10.1158/0008-5472.CAN-14-2524. Epub 2015 May 14.

19.

Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients.

Munsch C, Lauwers-Cances V, Lamant L, Gentil C, Rochaix P, Garrido I, Lopez R, Chevreau C, Paul C, Meyer N.

Dermatology. 2014;229(3):183-9. doi: 10.1159/000362902. Epub 2014 Aug 26.

PMID:
25171688
20.

[Radiotherapy as conservative therapy for sarcomas within the irradiated field].

Modesto A, Filleron T, Chevreau C, Le Péchoux C, Rochaix P, Le Guellec S, Ducassou A, Gangloff D, Ferron G, Delannes M.

Cancer Radiother. 2014 Jun;18(3):171-6. doi: 10.1016/j.canrad.2014.02.006. Epub 2014 Apr 18. French.

PMID:
24746453
21.

Role of radiation therapy in the conservative management of sarcoma within an irradiated field.

Modesto A, Filleron T, Chevreau C, Le Pechoux C, Rochaix P, Le Guellec S, Ducassou A, Gangloff D, Ferron G, Delannes M.

Eur J Surg Oncol. 2014 Feb;40(2):187-92. doi: 10.1016/j.ejso.2013.07.088. Epub 2013 Sep 26.

PMID:
24074728
22.

Dual role of sphingosine kinase-1 in promoting the differentiation of dermal fibroblasts and the dissemination of melanoma cells.

Albinet V, Bats ML, Huwiler A, Rochaix P, Chevreau C, Ségui B, Levade T, Andrieu-Abadie N.

Oncogene. 2014 Jun 26;33(26):3364-73. doi: 10.1038/onc.2013.303. Epub 2013 Jul 29.

PMID:
23893239
23.

High endothelial venule blood vessels for tumor-infiltrating lymphocytes are associated with lymphotoxin β-producing dendritic cells in human breast cancer.

Martinet L, Filleron T, Le Guellec S, Rochaix P, Garrido I, Girard JP.

J Immunol. 2013 Aug 15;191(4):2001-8. doi: 10.4049/jimmunol.1300872. Epub 2013 Jul 3.

24.

Statins Reduce Melanoma Development and Metastasis through MICA Overexpression.

Pich C, Teiti I, Rochaix P, Mariamé B, Couderc B, Favre G, Tilkin-Mariamé AF.

Front Immunol. 2013 Mar 13;4:62. doi: 10.3389/fimmu.2013.00062. eCollection 2013.

25.

High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes.

Martinet L, Le Guellec S, Filleron T, Lamant L, Meyer N, Rochaix P, Garrido I, Girard JP.

Oncoimmunology. 2012 Sep 1;1(6):829-839.

26.

Gene expression profiling on pre- and post-erlotinib tumors from patients with head and neck squamous cell carcinoma.

Thomas F, Delmar P, Vergez S, Rochaix P, Hennebelle I, McLoughlin P, Benlyazid A, Sarini J, Delord JP.

Head Neck. 2013 Jun;35(6):809-18. doi: 10.1002/hed.23036. Epub 2012 Jul 13.

PMID:
22791662
27.

CTNNB1 mutation analysis is a useful tool for the diagnosis of desmoid tumors: a study of 260 desmoid tumors and 191 potential morphologic mimics.

Le Guellec S, Soubeyran I, Rochaix P, Filleron T, Neuville A, Hostein I, Coindre JM.

Mod Pathol. 2012 Dec;25(12):1551-8. doi: 10.1038/modpathol.2012.115. Epub 2012 Jul 6.

28.

Stromal estrogen receptor-α promotes tumor growth by normalizing an increased angiogenesis.

Péqueux C, Raymond-Letron I, Blacher S, Boudou F, Adlanmerini M, Fouque MJ, Rochaix P, Noël A, Foidart JM, Krust A, Chambon P, Brouchet L, Arnal JF, Lenfant F.

Cancer Res. 2012 Jun 15;72(12):3010-9. doi: 10.1158/0008-5472.CAN-11-3768. Epub 2012 Apr 20.

29.

[In practice for the pathologist: practical and technical limitations].

Rochaix P.

Ann Pathol. 2011 Nov;31(5 Suppl):S43-5. doi: 10.1016/j.annpat.2011.08.018. Epub 2011 Sep 28. French. No abstract available.

PMID:
22054457
30.

Human solid tumors contain high endothelial venules: association with T- and B-lymphocyte infiltration and favorable prognosis in breast cancer.

Martinet L, Garrido I, Filleron T, Le Guellec S, Bellard E, Fournie JJ, Rochaix P, Girard JP.

Cancer Res. 2011 Sep 1;71(17):5678-87. doi: 10.1158/0008-5472.CAN-11-0431. Epub 2011 Aug 16.

31.

An alternative fixative to formalin fixation for molecular applications: the RCL2(®)-CS100 approach.

Denouël A, Boissière-Michot F, Rochaix P, Bibeau F, Boulle N.

Methods Mol Biol. 2011;724:297-307. doi: 10.1007/978-1-61779-055-3_19.

PMID:
21370021
32.

[Molecular diagnosis of unknown primary tumors].

Rochaix P.

Ann Pathol. 2010 Nov;30(5 Suppl 1):46-9. doi: 10.1016/j.annpat.2010.07.010. Epub 2010 Aug 21. French. No abstract available.

PMID:
21055543
33.

Systematic bioinformatics and experimental validation of yeast complexes reduces the rate of attrition during structural investigations.

Brooks MA, Gewartowski K, Mitsiki E, Létoquart J, Pache RA, Billier Y, Bertero M, Corréa M, Czarnocki-Cieciura M, Dadlez M, Henriot V, Lazar N, Delbos L, Lebert D, Piwowarski J, Rochaix P, Böttcher B, Serrano L, Séraphin B, van Tilbeurgh H, Aloy P, Perrakis A, Dziembowski A.

Structure. 2010 Sep 8;18(9):1075-82. doi: 10.1016/j.str.2010.08.001.

34.

Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.

Vergez S, Delord JP, Thomas F, Rochaix P, Caselles O, Filleron T, Brillouet S, Canal P, Courbon F, Allal BC.

Clin Cancer Res. 2010 Sep 1;16(17):4434-45. doi: 10.1158/1078-0432.CCR-09-2795. Epub 2010 Jul 26.

35.

Trastuzumab induced in vivo tissue remodelling associated in vitro with inhibition of the active forms of AKT and PTEN and RhoB induction in an ovarian carcinoma model.

Delord JP, Quideau S, Rochaix P, Caselles O, Couderc B, Hennebelle I, Courbon F, Canal P, Allal BC.

Br J Cancer. 2010 Jun 29;103(1):61-72. doi: 10.1038/sj.bjc.6605699. Epub 2010 Jun 1.

36.

Melanoma cells treated with GGTI and IFN-gamma allow murine vaccination and enhance cytotoxic response against human melanoma cells.

Sarrabayrouse G, Pich C, Moriez R, Armand-Labit V, Rochaix P, Favre G, Tilkin-Mariamé AF.

PLoS One. 2010 Feb 3;5(2):e9043. doi: 10.1371/journal.pone.0009043.

37.

Histological regression in primary melanoma: not a predictor of sentinel lymph node metastasis in a cohort of 397 patients.

Socrier Y, Lauwers-Cances V, Lamant L, Garrido I, Lauwers F, Lopez R, Rochaix P, Chevreau C, Payoux P, Viraben R, Paul C, Meyer N.

Br J Dermatol. 2010 Apr;162(4):830-4. doi: 10.1111/j.1365-2133.2009.09606.x. Epub 2009 Dec 21.

PMID:
20030641
38.

Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer.

Laklai H, Laval S, Dumartin L, Rochaix P, Hagedorn M, Bikfalvi A, Le Guellec S, Delisle MB, Schally AV, Susini C, Pyronnet S, Bousquet C.

Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17769-74. doi: 10.1073/pnas.0908674106. Epub 2009 Oct 1.

39.

Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women.

Desmetz C, Bascoul-Mollevi C, Rochaix P, Lamy PJ, Kramar A, Rouanet P, Maudelonde T, Mangé A, Solassol J.

Clin Cancer Res. 2009 Jul 15;15(14):4733-41. doi: 10.1158/1078-0432.CCR-08-3307. Epub 2009 Jul 7.

40.

Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.

Thomas F, Rochaix P, White-Koning M, Hennebelle I, Sarini J, Benlyazid A, Malard L, Lefebvre JL, Chatelut E, Delord JP.

Eur J Cancer. 2009 Sep;45(13):2316-23. doi: 10.1016/j.ejca.2009.05.007. Epub 2009 Jun 10.

PMID:
19523815
41.

Proteomic analysis of RCL2 paraffin-embedded tissues.

Bellet V, Boissière F, Bibeau F, Desmetz C, Berthe ML, Rochaix P, Maudelonde T, Mangè A, Solassol J.

J Cell Mol Med. 2008 Oct;12(5B):2027-36. doi: 10.1111/j.1582-4934.2008.00186.x.

42.

[A novel fixed paraffin-embedded tissue processing for proteomic analysis].

Bellet V, Rochaix P, Mange A, Solassol J.

Ann Biol Clin (Paris). 2008 Jul-Aug;66(4):401-7. doi: 10.1684/abc.2008.0249. French.

43.

KBA.62: a useful marker for primary and metastatic melanomas.

Pagès C, Rochaix P, al Saati T, Valmary-Degano S, Boulinguez S, Launay F, Carle P, Lauwers F, Payoux P, Le Guellec S, Brousset P, Lamant L.

Hum Pathol. 2008 Aug;39(8):1136-42. doi: 10.1016/j.humpath.2007.12.006. Epub 2008 May 20.

PMID:
18495211
44.

Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.

Asnacios A, Courbon F, Rochaix P, Bauvin E, Cances-Lauwers V, Susini C, Schulz S, Boneu A, Guimbaud R, Buscail L.

J Clin Oncol. 2008 Feb 20;26(6):963-70. doi: 10.1200/JCO.2007.12.7431.

PMID:
18281671
45.

Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin.

Ravel D, Dubois V, Quinonero J, Meyer-Losic F, Delord J, Rochaix P, Nicolazzi C, Ribes F, Mazerolles C, Assouly E, Vialatte K, Hor I, Kearsey J, Trouet A.

Clin Cancer Res. 2008 Feb 15;14(4):1258-65. doi: 10.1158/1078-0432.CCR-07-1165.

46.

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

Balin-Gauthier D, Delord JP, Pillaire MJ, Rochaix P, Hoffman JS, Bugat R, Cazaux C, Canal P, Allal BC.

Br J Cancer. 2008 Jan 15;98(1):120-8. doi: 10.1038/sj.bjc.6604134. Epub 2008 Jan 8.

47.

Pilot study of neoadjuvant treatment with erlotinib in nonmetastatic head and neck squamous cell carcinoma.

Thomas F, Rochaix P, Benlyazid A, Sarini J, Rives M, Lefebvre JL, Allal BC, Courbon F, Chatelut E, Delord JP.

Clin Cancer Res. 2007 Dec 1;13(23):7086-92.

48.

Gene expression profiling of human melanoma cell lines with distinct metastatic potential identifies new progression markers.

Bertucci F, Pages C, Finetti P, Rochaix P, Lamant L, Devilard E, Nguyen C, Houlgatte R, Birnbaum D, Xerri L, Brousset P.

Anticancer Res. 2007 Sep-Oct;27(5A):3441-9.

49.

Adenoid cystic carcinoma of the lung: interest of 18FDG PET/CT in the management of an atypical presentation.

Campistron M, Rouquette I, Courbon F, Chabbert V, Rochaix P, Prévot G, Laroumagne S, Têtu L, Didier A, Mazières J.

Lung Cancer. 2008 Jan;59(1):133-6. Epub 2007 Jul 20.

PMID:
17640764
50.

Is there an immunohistochemical technique definitively valid in epidermal growth factor receptor assessment?

Penault-Llorca F, Cayre A, Arnould L, Bibeau F, Bralet MP, Rochaix P, Savary J, Sabourin JC.

Oncol Rep. 2006 Dec;16(6):1173-9.

PMID:
17089034

Supplemental Content

Loading ...
Support Center